Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B

Exelixis reported solid earnings, with management emphasizing plans to expand its oncology franchises through internal drug development, selective business development and potential collaborations. The article frames the results and growth strategy as supportive of a potential retest of prior share-price highs, though no financial figures or formal guidance were provided in the supplied text.